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Hypoxia-inducible factor-1 (HIF-1) plays important roles in regulating radiosensitivity, making it a potentially promising target
for tumour radiosensitisation. Here, we discuss the rationale for, and the potential pitfalls of, combining HIF-1 blockade with
radiotherapy. In doing so, we describe clinical scenarios in which HIF-1 inhibition might optimise tumour radiosensitivity.
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Hypoxia is an important contributor to tumour radioresistance
(Brizel et al, 1997). Oxygen increases the cytotoxicity of radiation,
resulting in roughly a three-fold difference in radiosensitivity
between hypoxic and aerobic cells. This phenomenon, termed the
oxygen effect, is widely attributed to oxygen’s ability to chemically
modify radiation-induced DNA damage, creating adducts that are
not easily repaired by cells (Roots and Smith, 1974).
As we have come to better understand how tumours respond
and adapt to hypoxia, it has become apparent that there may also
be biological mechanisms that contribute to the oxygen effect.
Owing to an imbalance in oxygen supply and demand, most
solid tumours are hypoxic (Dewhirst, 2003). As a result, signaling
pathways stimulated by hypoxia are commonly activated in
tumours (Harris, 2002). Arguably, the best understood of these
pathways is controlled by hypoxia-inducible factor-1 (HIF-1).
Hypoxia-inducible factor-1 is a transcription factor activated by
hypoxia that modulates more than 100 genes involved in
regulating important processes such as metabolism, proliferation,
apoptosis, and angiogenesis (Semenza, 2003).
Teleologically, the downstream effects of HIF-1 serve to help the
cell adapt to hypoxic stress. In doing so, they change the tumour
phenotype in ways that might also impact radiosensitivity; some
positively, and some negatively (Table 1). As some of these HIF-1-
mediated processes will be more predominant in certain tumours,
it is likely that HIF-1 may have varying effects on radiosensitivity
from tumour to tumour. In fact, there are some clinical data, which
support this concept. In oropharyngeal cancer, high levels of HIF-1
expression have been shown to predict for poor local control in
advanced disease (Aebersold et al, 2001), while predicting for
superior local control in early-stage disease (Fillies et al, 2005).
The above data suggest that HIF-1 influences tumour radio-
sensitivity, but that the degree and direction of that influence may
be dependent on context. Here, we hope to begin building an
understanding for how the tumour phenotype affects the relation-
ship between HIF-1 and tumour radiosensitivity. We will attempt
to extrapolate from this how HIF-1 blockade might best be used to
capitalise on its potential for tumour radiosensitisation.
HOW RADIATION AFFECTS HIF-1
As shown by the clinical data mentioned above, pretreatment
HIF-1 expression levels influence local control for irradiated
tumours. This raises the question of how HIF-1 activity varies
during and after radiotherapy, as these are the times when the
protein should function as a modulator of radioresistance. As it
turns out, radiation causes HIF-1 expression levels to increase in
tumours (Moeller et al, 2004). The effect is dose-responsive, but
does not appear to depend on dose fractionation. The upregulation
begins as early as 24h after treatment, and has been shown to
endure for as long as 1 week. Coincident with this effect, several
important downstream targets of HIF-1 are also upregulated in
irradiated tumours. These proteins, including vascular endothelial
growth factor (VEGF), plasminogen activator inhibitor-1, and
carbonic anhydrase IX, serve as the longer-lived mediators of the
radiation-induced HIF-1 effect.
The mechanisms behind this effect are interesting and,
importantly, reveal nuances that may be clinically relevant. Two
pathways have been worked out to explain how irradiation leads to
HIF-1 activation (Moeller et al, 2004). The two share a common
origin: radiation-induced tumour reoxygenation. As mentioned
above, radiation preferentially kills well-oxygenated and highly
metabolic tumour cells. The death of these cells frees up oxygen to
distribute to regions of the irradiated tumour that were previously
hypoxic. Tumours are also debulked by the cell death occurring
after radiation, freeing up space for vessels to expand and improve
blood flow and nutrient delivery to starved regions of tumour
tissue. The end result is that oxygen levels in tumour tissue tend to
be higher after irradiation, an effect termed ‘reoxygenation’.
Paradoxically, increasing tumour oxygenation in this way causes
activation of the HIF-1 pathway, which is normally responsive to
decreased oxygenation. Part of the explanation for this comes
from the oxidative stress generated during tumour reoxygenation.
After irradiation, during reoxygenation, free radical species
accumulate in tumour tissue and lead to overexpression of
HIF-1 (Moeller et al, 2004). It is unknown precisely through
what mechanism this occurs, but several theories have been
put forward. One postulates that free radical species generated
in the mitochondria during hypoxia are the signal used by the
cell to sense oxygen deprivation and that they are, therefore,
capable themselves of mimicking hypoxia (Chandel et al, 2000).
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machinery that breaks down HIF-1 during normoxia, causing
HIF-1 to function as though the cells were hypoxic (Metzen et al,
2003). But whatever the cause, reoxygenation clearly changes
the redox environment in irradiated tumours, causing accumula-
tion of HIF-1.
Apart from setting off this oxidative pathway, reoxygenation
also affects the translational machinery in the irradiated tumour
cell, further contributing to the radiation-induced activation of
the HIF-1 pathway. When a cell becomes stressed, it strives to
conserve energy by, in part, slowing down protein synthesis.
This is accomplished through a variety of mechanisms (Wouters
et al, 2005). One involves dynamic regulation of protein translation
through so-called stress granules. Stress granules are cytosolic
polymers made up of mRNA, ribosomal subunits, and various
other proteins (Kedersha et al, 1999). They serve as points of
triage during stress, differentiating which transcripts need
urgent translation and which can be sequestered in the granule
for translation at a more favourable point in time (Kedersha
and Anderson, 2002). As long as the cell has not been irreversibly
damaged, the granules depolymerise once the stress is
alleviated, and the once-sequestered transcripts go on to be
translated normally.
Stress granules play a role in activating the HIF-1 pathway after
tumours are irradiated (Moeller et al, 2004). They form in response
to hypoxia and bind, among other things, mRNA transcribed off of
HIF-1-regulated genes. This effect is not absolute, as proteins
downstream of HIF-1 are synthesised during hypoxia. However,
the magnitude of their upregulation is blunted by the activity
of the stress granules. As proof of this, when reoxygenation causes
the stress granules to disassemble, new protein translation causes
synthesis of downstream HIF-1 targets to increase approximately
two-fold. This provides the second mechanism through which
radiation upregulates HIF-1 activity in tumours.
In summary, radiation causes upregulation of the HIF-1
pathway in tumours through two mechanisms dependent on
reoxygenation. The resulting increased levels of free radical species
within the tumour caused the HIF-1 protein to accumulate. At the
same time, stress granules are depolymerised, reversing a partial
blockade on protein synthesis in the HIF-1 pathway. Together,
these effects significantly upregulate the HIF-1 pathway in the
irradiated tumour.
HOW HIF-1 AFFECTS TUMOUR RADIATION
RESPONSE
As discussed above, data exists to suggest that HIF-1 plays a role in
determining tumour radiosensitivity. Until recently, no study had
been carried out to examine the mechanisms behind this rela-
tionship. These details are important to understand as they may
lend further insight into why HIF-1 may differentially radiosensitise
certain tumours. Moreover, this knowledge may reveal which
tumours might be maximally radiosensitised by HIF-1 blockade.
To date, the effect HIF-1 has on tumour radiosensitivity has
been ascribed to four different processes: its impact on apoptosis,
metabolism, proliferation, and the tumour vasculature. It is not yet
known whether any of these contributes more or less than the
others to the overall effect so, for now, each should be considered
as important as the next. We will examine each, in turn, below.
In general, HIF-1 has a complicated relationship with apoptosis.
As mentioned above, HIF-1 has been shown in different situations
to be both proapoptotic and antiapoptotic. In the irradiated
cell, however, HIF-1 appears to have a net proapoptotic effect.
Normally, ionising radiation induces breaks in DNA that are
sensed by the cell, setting off a cascade of molecular reactions that
help determine which of the many possible fates (i.e. repair,
apoptosis, mitotic death) the cell should meet. For cells that
eventually undergo apoptosis, one of the most important events in
this cascade is the activation of p53.
HIF-1 exerts its effect on radiation-induced apoptosis, at least in
part, through interacting with p53. Tumour cells exposed to both
hypoxia and radiation undergo apoptosis through a p53- and HIF-
1-dependent mechanism (Moeller et al, 2005b). HIF-1 enhances
phosphorylation of p53 in the irradiated cell, promoting caspase
cleavage and, eventually, apoptosis. Of note, HIF-1 appears to have
no impact on radiation-induced apoptosis in the p53-null human
prostate cell line, PC-3. When p53 is reintroduced to the PC-3
line, it regains HIF-1-dependent sensitivity to radiation-induced
apoptosis. It remains to be seen whether the link between HIF-1
and radiation-induced apoptosis is as closely tied to p53 in other
cell lines. There is ample reason to believe it may not be, as HIF-1
is known to affect several p53-independent apoptotic mechanisms,
such as BNIP3 (Bruick, 2000).
HIF-1 can also affect tumour cell clonogenicity following
irradiation by altering cellular metabolism. It governs the
expression of a host of proteins involved in glycolysis, and serves
an important role in maintaining energy levels during hypoxia.
Consequently, tumours deficient in HIF-1 have difficulty main-
taining ATP levels (Griffiths et al, 2002; Moeller et al, 2005b) – a
state which might increase clonogenicity after irradiation (Luk and
Sutherland, 1987). Indeed, if tumour cells are made to be hypoxic
in a glucose-limiting environment, without the aid of HIF-1’s
glycolysis-promoting effects, their metabolic rates drop, ATP levels
fall, and in vitro clonogenicity increases (Moeller et al, 2005b).
HIF-1 also affects tumour cell clonogenicity by altering the
kinetics of cellular proliferation. This effect is highly dependent on
the local microenvironment and, therefore, varies considerably
from place to place within a tumour. In regions where both
hypoxia and glucose are limited, HIF-1 maintains tumour
proliferation, likely by supporting bioenergetics. In regions where
hypoxia alone is limiting, HIF-1 promotes cell cycle blockade,
likely by modulating p21 and p27 (Goda et al, 2003). The overall
impact of these combined effects is that HIF-1 radiosensitises
tumours by keeping cells proliferative in nutrient-depleted regions
of the tumour tissue (Moeller et al, 2005b).
The final known mechanism linking HIF-1 activity to tumour
radiosensitivity involves the regulation of vascular radiosensi-
tivity. The degree to which the tumour vasculature is damaged
by radiation has been shown to be an important determinant
of overall responsiveness of tumours to ionising radiation in
animal models (Garcia-Barros et al, 2003). The radiosensitivity
of endothelial cells within a tumour, in turn, appears to be
highly dependent on their exposure to proangiogenic stimulants.
Proangiogenic cytokines, such as VEGF and basic fibroblast
growth factor, have been found to induce significant radio-
protection in endothelial cells (Gorski et al, 1999; Paris et al, 2001).
HIF-1, which promotes the expression of a variety of
proangiogenic cytokines, is poised to be a major regulator of this
behavior in tumours. Conditioned media taken from wild-type
tumour cells is much more efficient at inducing resistance to
radiation-induced death in endothelial cells than is that taken from
Table 1 HIF-1 modulates many processes, which might cause tumours
to be more or less radiosensitive
HIF-1-mediated effect
Potential impact on
radiosensitivity
Cell cycle arrest (Goda et al, 2003) Decreased
Proapoptotic (Carmeliet et al, 1998) Increased
Antiapoptotic (Piret et al, 2004) Decreased
Enhanced glycolysis (Semenza et al, 1994) Increased
Angiogenesis (Carmeliet et al, 1998) Decreased
(Gorski et al, 1999)
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finding, the vasculature of HIF-1-deficient tumours under-
goes significantly more regression following irradiation than does
the vasculature of their wild-type controls (Moeller et al,
2005b). Through its protective effects on the surrounding vascular
endothelium, then, HIF-1 serves as a powerful radioprotective
factor for tumours.
The above data show that HIF-1 has divergent effects on
radiosensitivity: sensitisation of tumour cells and protection of
stromal endothelial cells (Figure 1). It is critical to understand how
these divergent mechanisms come together to bring about a
change in tumour radiosensitivity. If the net result of HIF-1
activity is to promote radioresistance in tumours, HIF-1 blockade
would seem to be a promising strategy for tumour radiosensitisa-
tion. However, three of the four HIF-1-mediated effects described –
enhancing apoptosis, metabolism, and proliferation – result in
tumour radiosensitisation, while only one – vascular protection –
promotes tumour radioresistance. One might predict from this,
then, that HIF-1 blockade could interfere with radiotherapy.
Studies have shown, however, that HIF-1-deficient tumours are
more radiosensitive than their wild-type counterparts (Zhang et al,
2004; Moeller et al, 2005b; Williams et al, 2005).
How can this apparent discrepancy be explained? One
possibility is that HIF-1 promotes tumour radioresistance through
some other effects, not yet realised or described. Another is that
the vascular radiosensitisation caused by HIF-1 blockade is a
more powerful influence on tumour radiosensitivity than are the
other factors discussed. There are some data to support these
hypotheses. It has been shown in one experimental system
that eliminating the hypoxic fraction of a HIF-1-deficient tumour
immediately prior to irradiation does not alter the tumour
regrowth rate after treatment (Williams et al, 2005). What this
experiment suggests is that, in contrast to wild-type tumours, the
hypoxic fraction of HIF-1-deficient tumours does not contribute to
tumour regrowth after irradiation. One might surmise from this
that even though HIF-1 blockade causes some degree of radio-
resistance in the hypoxic cell, the combination of hypoxia and
HIF-1 inhibition render that cell, overall, nonclonogenic after
irradiation. Moreover, since the radiosensitising effects of HIF-1
blockade occur at a distance – damaging all tumour cells fed by the
affected vasculature – the positive effects apply more broadly over
the tumour than do the negative effects. Whatever the explanation,
these data suggest that HIF-1 blockade is a viable strategy for
tumour radiosensitisation.
CLINICAL CORRELATION
There are lessons to be learned from the mechanisms connecting
radiation to HIF-1, and HIF-1 to radiosensitivity, which may be
relevant for the use of HIF-1 blockade as a tumour radiosensitiser
(Table 2). First, the degree of tumour hypoxia is likely to play
a role in determining how HIF-1 blockade influences tumour
radiosensitivity. Of course, there are numerous hypoxia-indepen-
dent stimuli for HIF-1 activation (Dery et al, 2005). As a result,
tumours that are well-oxygenated yet signal robustly through
PI3K, for example, may have sufficient HIF-1 activity to influence
their radiosensitivity. However, tumours need to be hypoxic to
undergo radiation-induced HIF-1 activation since reoxygenation
is required to initiate this pathway. Therefore, both baseline
HIF-1 expression levels and oxygenation are likely important
determinants of how tumour radiosensitivity will respond to HIF-1
blockade. Second, since stress granules do not depolymerise
after a cell experiences a lethal threat, tumours need to be made up
of mostly viable tissue in order to maximally activate the
HIF-1 pathway after radiation. Therefore, tumours with low HIF-
1 activity levels, little or no hypoxia, or tumours with vast amounts
of necrosis are unlikely to undergo much HIF-1 activation
in response to radiotherapy. Consequently, HIF-1 blockade is
less likely to add benefit to radiation in such tumours. Third,
since HIF-1 collaborates with p53 to promote apoptosis,
scheduling HIF-1 inhibition with radiation may be a challenge in
p53-positive tumours.
Considerations such as these may influence how HIF-1
blockade is used in the clinic. This is particularly relevant
now, as there are several agents currently being developed as
potential HIF-1 inhibitors for use in oncology. One frontrunner
is topotecan, a topoisomerase I inhibitor which blocks
HIF-1 translation at doses lower than those required for the
drug to damage DNA (Rapisarda et al, 2004). Topotecan is
VEGF p21 p53
CeII death
CeII death
DevascuIarisation
Hypoxia
ATP
p
HIF-1
Figure 1 A representation of HIF-1’s effects on radiosensitivity for a
HIF-1-expressing tumour cell (blue), a non-HIF-1-expressing tumour cell
(green), and a tumour vessel (red). Dashed arrows depict the normal
effects of ionising radiation. Dotted arrows show HIF-1-mediated pathways
that sensitise tumours to radiation. Solid arrows show HIF-1-mediated
pathways that protect tumours from radiation, whose blockade might
radiosensitise tumours. ‘VEGF’ symbolises the proangiogenic pathway, ‘p21’
the mitotic pathway, ‘p-p53’ the apoptotic pathway, and ‘ATP’ the
metabolic pathway. Note that in this schematic, non-HIF-1-expressing cells
are still radiosensitised by HIF-1 blockade.
Table 2 Characteristics of tumours that might conceivably limit the influence of HIF-1 on radiosensitivity and/or the efficacy of combined HIF-1 blockade
and radiotherapy
Tumour characteristic Potential effect Potential consequence Therapeutic implication
Scant hypoxia Limited reoxygenation after irradiation Limited HIF-1 activation after irradiation Limited additional benefit of HIF-1 blockade
Abundant necrosis Stress granules fail to depolymerize Limited HIF-1 activation after irradiation Limited additional benefit of HIF-1 blockade
p53 Positive HIF-1/p53 interaction promotes
apoptosis
Enhanced radiation-induced apoptotic cell death HIF-1 blockade may decrease apoptotic cell
death
Poor anatomic location — HIF-1 blockade may radiosensitize some normal
tissues
HIF-1 blockade may fail to widen the
therapeutic ratio
HIF-1 and radiosensitivity
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inhibitor. A second promising class of HIF-1-inhibiting agents
undergoing active clinical development are the analogues
of 2-methoxyestradiol from EntreMed, Inc, which downregulate
HIF-1 at the post-translational level (Mabjeesh et al, 2003). A large
number of other ‘hits’ from various small molecule screens have
also been presented as potential clinical HIF-1 inhibitors. Only
time will tell which of these, if any, are efficacious in human
tumours and augment the effects of standard cytotoxic therapies
such as radiation.
Another potential strategy to counter the radioprotective effects
of HIF-1 would be to inhibit the mechanisms by which radiation
causes HIF-1 activation. This has been done in a preclinical model
using a manganese porphyrin compound – a mimetic of super-
oxide dismutase – to scavenge the free radical species generated
during radiation-induced reoxygenation (Moeller et al, 2004).
Combining these agents with radiotherapy delays tumour regrowth
significantly over that seen with either treatment alone (Moeller
et al, 2005a). As the manganese porphyrin compounds also protect
normal tissues from radiation damage, this may be a powerful
clinical therapeutic option.
Finally, it is worth mentioning here that there are no data yet on
whether HIF-1 blockade might impact normal tissue radio-
sensitivity. As HIF-1 is not typically active in most healthy normal
tissues, one would expect that its inhibition would not affect
normal tissue radiosensitivity. There may, however, be exceptions
to this rule. There are some normal tissues, such as the liver and
the thymus, that are hypoxic at baseline (Arteel et al, 1995; Hale
et al, 2002). HIF-1 may play a homeostatic role in such organs,
potentially important in the recovery from radiation damage.
Indeed, HIF-1 has been implicated in the response to injury and
inflammation in normal tissues (Maeno et al, 2005), processes
which have much in common with the response to radiation
damage. It remains an important yet unresolved issue to determine
whether inhibiting the function of HIF-1 in normal tissues would
impair their ability to heal after being irradiated.
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